Let's start with the headline nobody in Washington wants to print: marijuana is still illegal. Not "illegal-ish." Not "illegal with an asterisk." Federally, under the Controlled Substances Act, cannabis remains a Schedule I narcotic, officially grouped with heroin and LSD, officially declared to have no accepted medical use. That fact hasn't moved an inch this year, despite a summer's worth of DEA hearings, legal filings, and breathless coverage suggesting otherwise.
I want to be precise about what actually happened, because the gap between what occurred and what got reported is the whole story. Earlier this year, the DEA finalized a narrow rule shifting FDA-approved marijuana medications and marijuana produced by state-licensed medical operators who hold DEA registration into Schedule III. That's it. That's the win. A small, heavily gated lane for pharmaceutical-grade and specifically licensed medical product got bumped down two schedules. Everything else you and I know as cannabis, every dispensary purchase, every home grow, every joint passed at a barbecue, sits exactly where it sat under Nixon.
So when I hear people describe the DEA's ongoing administrative hearing as "the rescheduling hearing," as if the fate of cannabis nationwide hangs on the outcome, I have to push back. The proceeding underway right now is about whether marijuana as a whole, the substance itself as defined in the CSA, gets moved to Schedule III. The narrow medical carve-out already happened and isn't up for debate. Everything discussed in that DEA hearing room in Arlington is downstream of a decision that will not touch state-legal adult-use markets, will not resolve the conflict between state and federal law, and will not release a single person from prison for a cannabis charge.
Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, wrote an op-ed for Marijuana Moment describing what it was actually like inside that hearing room, and it's worth sitting with. She showed up at 7:15 in the morning outside DEA headquarters to attend one of the more consequential federal marijuana proceedings in decades. Her organization had requested to participate as an interested party. Denied. So were NORML, the Marijuana Policy Project, the Cannabis Regulators of Color Coalition, the Latino Cannabis Alliance, the Law Enforcement Action Partnership, Doctors for Drug Policy Reform, the Parabola Center for Law and Policy, Supernova Women, and Students for Sensible Drug Policy.
Read that list again. That's not a random assortment of hangers-on. That's a big chunk of the institutional infrastructure that spent decades building the case for reform, denied a seat at the table on the exact question they've been organizing around. The DEA designated seven parties to participate in the hearing. Every one of them opposes rescheduling. Not a mixed bag, not a range of perspectives weighted toward caution, a unanimous bloc of opponents given the exclusive right to call witnesses, introduce evidence, and cross-examine the government's own experts.
Then there's the access problem, which is its own small scandal. No livestream. No video broadcast. No public audio feed. If you wanted to know what was happening inside that room, you had to physically be there, admitted a handful at a time on a first-come, first-served basis starting at 9 a.m. Packer made it in for the first two days. On the third, she was turned away, told the administrative law judge had barred public attendees after 8:50 a.m., a restriction nobody had bothered to announce beforehand. A federal proceeding this significant, run like a DMV line with a secret cutoff time.
I don't think that's incompetence. I think it's design. Keep the room small, keep the cameras out, keep the designated parties uniformly opposed, and you control the administrative record without technically breaking any rules. Whatever recommendation the administrative law judge eventually sends to the DEA gets built almost entirely from testimony favoring the status quo, dressed up as procedural neutrality.
The testimony that did make it into the record tells you where the government wanted the conversation to stay. Dr. Dominic Chiapperino, who directs the Controlled Substances Section at the FDA, walked through the agency's scientific and medical review process, the methodology behind determining accepted medical use and abuse potential. Dr. Corey Burchman followed with clinical testimony, describing patients he's helped transition off opioids and onto cannabis. Useful information. Also exactly the kind of narrow, clinical framing that keeps the hearing inside a lab-coat box.
What never came up, according to Packer's account, is the part of this story that actually affects people: the decades of arrests, convictions, incarceration, and collateral consequences that criminalization has inflicted on individuals, families, and entire communities. No discussion of the racial disparities that have defined marijuana enforcement since the beginning. No mention of the Nixon-era Shafer Commission, which recommended against criminalizing personal possession over fifty years ago and got ignored. No accounting of what the dozens of states that have already legalized and regulated cannabis have actually learned from doing it.
Government counsel opened the hearing by framing the whole exercise as being about "regulation, not legalization," and I'll give them this much: it's an honest description of how limited the proceeding actually is. But regulation and legalization aren't opposing teams. Treating them as mutually exclusive is a rhetorical trick, a way to sound reasonable and technocratic while sidestepping the actual policy question the public keeps asking, which is why the plant remains criminalized at all when a supermajority of the country has already decided it shouldn't be.
Here's the part that should deflate anyone hoping this hearing changes their life anytime soon: even a favorable outcome doesn't end federal prohibition. Moving marijuana to Schedule III would still leave it a federally controlled substance, still leave the conflict between state legalization and federal law unresolved, still leave people prosecutable under federal statute. The administrative law judge issues a recommendation. The DEA decides whether to adopt it. Whatever the DEA decides gets challenged in court, almost certainly. We are years, not months, from any of this touching the ground.
I've said it before and this hearing only confirms it: rescheduling was never going to be the finish line. It's a bureaucratic reshuffling that lets the federal government claim it's "following the science" while leaving the actual machinery of prohibition, the arrests, the industry's inability to bank normally, the tax penalties under section 280E, fully intact for anyone operating outside that narrow pharmaceutical lane. Actual reform, the kind that ends criminal exposure and starts repairing the damage prohibition has done, requires Congress. Bills like the MORE Act and the Cannabis Administration and Opportunity Act exist for exactly that reason, and they're gathering dust while everyone's attention gets pointed at a hearing room in Arlington with the cameras turned off.
It's worth understanding why Schedule III, even the narrow slice of it that already took effect, matters so much to certain players and so little to everyone else. Schedule III substances face far lighter restrictions than Schedule I, they're formally recognized as having accepted medical use, and businesses that touch them stop getting hammered by section 280E of the federal tax code, the provision that currently bars anyone trafficking a Schedule I or II substance from deducting ordinary business expenses. That's a real, material benefit, but it flows almost entirely to pharmaceutical companies and the narrow class of state-licensed medical operators who qualify under the DEA's new registration scheme. Your neighborhood dispensary selling adult-use flower gets none of it. Neither does anyone still facing federal exposure for cultivation or distribution outside that lane.
I understand why some longtime activists describe this outcome as insulting rather than encouraging. People spent decades marching, organizing, and in plenty of cases going to prison to make the argument that cannabis prohibition itself was the injustice, not just the absence of a pharmaceutical pathway for it. Watching the federal government respond to that decades-long argument with a rule that mostly benefits drug manufacturers and a narrow slice of licensed medical operators feels, to a lot of people who did the actual work, like being handed a consolation prize for a fight they were told they'd already won in the court of public opinion. The gap between what the movement asked for and what the government delivered is exactly the kind of gap that breeds cynicism, and cynicism, once it sets in, is hard to undo.
So yes, I called this a nothingburger, and I stand by it. Not because the process is meaningless on paper, but because the people running it built it to produce a predetermined, minimal outcome while looking procedurally legitimate. Seven witnesses, zero of whom favor reform. No public livestream. An undisclosed door-locking time. A framing that walls off the actual question everyone wants answered. That's not a serious reckoning with fifty years of failed drug policy. That's theater, and the fact that we're all still watching it, still treating every DEA hearing date like a countdown to freedom, tells you how thoroughly the goalposts have been moved.
The real fight was never going to happen in that room. It happens in Congress, in state legislatures, in the record we keep of what prohibition actually cost. Keep an eye on the hearing if you want, but don't mistake the show for the substance.
THE DEA RESCHEDULING HEARINGS, READ ON...
THE DEA RESCHEDLING THEATER, WHAT IS GOING ON?
